ADMA Biologics, Inc.
Every calculator, already run for ADMA
Open the full toolkit →You have the numbers on ADMA. Get the argument.
A written report on which of these readings actually decide the outcome for ADMA Biologics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering ADMAAnalyst Price Target Disagreement for ADMA Biologics, Inc.
Wall Street's bull case implies +122% from the current price; the bear case implies +27%. A 95% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also de…
ADMA — frequently asked
Is ADMA a buy right now?
Wall Street's consensus rating on ADMA Biologics, Inc. is Buy across 5 analysts, with a mean price target of $17.00 (+80% vs. the current $9.47). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ADMA overvalued?
ADMA trades at 13.5x trailing earnings, against a DCF fair value of $9 per share. The current price implies 6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ADMA's next earnings date?
ADMA Biologics, Inc. is next scheduled to report earnings around Nov 4, 2026. A full ADMA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for ADMA Biologics, Inc.?
Analysts covering ADMA Biologics, Inc. (ADMA) range from a bear-case target of $12.00 to a bull-case high of $21.00, with a mean consensus target of $17.00 across 5 analysts. The spread of $9.00 (95% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ADMA Biologics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ADMA Biologics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ADMA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ADMA Biologics, Inc., in minutes. 3 free reports included with every account — no credit card required.